Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Colorectal Neoplasms 44Squamous Cell Carcinoma of Head and Neck 23Carcinoma, Non-Small-Cell Lung 23Head and Neck Neoplasms 13Pancreatic Neoplasms 11Neoplasm Metastasis 10Carcinoma, Squamous Cell 8Neoplasms 7Lung Neoplasms 7Colonic Neoplasms 7Rectal Neoplasms 6Esophageal Neoplasms 5Carcinoma 5Recurrence 4Carcinoma, Renal Cell 4Stomach Neoplasms 3Neoplasms, Squamous Cell 3Hereditary Sensory and Autonomic Neuropathies 3Glioblastoma 3Gastrointestinal Neoplasms 3Esophageal Squamous Cell Carcinoma 3Colorectal Cancer Metastatic 3Breast Neoplasms 3Tongue Neoplasms 2Sarcoma 2Salivary Gland Neoplasms 2Ovarian Neoplasms 2Oligodendroglioma 2Melanoma 2Glioma 2

Interventions

olaparib 1oblimersen 1lutetium Lu 177 dotatate 1Fluorodeoxyglucose F18 1FPP(RGD)2 1Erlotinib Hydrochloride 1Epirubicin 1Docetaxel 1Cetuximab 1Carboplatin 1Capecitabine 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Esthesioneuroblastoma, Olfactory × Cetuximab × Clear all
NCT00101348 2014-06-11

Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
66 enrolled
CNSGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Salivary Gland Neoplasms, Esthesioneuroblastoma, Olfactory

Data powered by HemOnc (CC BY 4.0) Colophon âš¡